Active	Status	Sponsor type	Region	Phase	Filter
14 Active 6 Inactive 20 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

14 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bowlus, Christopher L
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)	Active, not recruiting	3	238	Europe, Canada, Japan, US, RoW	Linerixibat, Placebo	GlaxoSmithKline	Pruritus	10/24	01/25
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study	Recruiting	3	251	Europe, Canada, Japan, US, RoW	Linerixibat	GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited	Cholestasis	02/27	02/27
SHIP, NCT03561584: Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis	Recruiting	2	42	US	Sulfasalazine, Azulfidine, Placebo	Brigham and Women's Hospital	Primary Sclerosing Cholangitis	09/24	11/24
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC	Active, not recruiting	2	60	US	Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo	Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.	Primary Biliary Cholangitis	11/24	02/25
SPRING, NCT04595825 / 2019-002945-39: CM-101 in PSC Patients -The Study	Active, not recruiting	2	68	Europe, US, RoW	Anti-human CCL24 monoclonal antibody (CM-101), Placebo	ChemomAb Ltd., ChemomAb Ltd	Primary Sclerosing Cholangitis	09/24	09/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC	Not yet recruiting	2	87	US	LB-P8 low-dose, LB-P8 high-dose, Placebo	LISCure Biosciences	Primary Sclerosing Cholangitis (PSC)	03/28	02/29
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects	Recruiting	2	240	US, RoW	HM15211, Placebo of HM15211	Hanmi Pharmaceutical Company Limited	NASH - Nonalcoholic Steatohepatitis	05/26	11/26
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH	Active, not recruiting	2	271	Europe, Canada, Japan, US, RoW	GSK4532990, Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease	12/25	03/26
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis	Active, not recruiting	1/2	42	US	CNP-104, Placebo	COUR Pharmaceutical Development Company, Inc.	Primary Biliary Cholangitis	01/26	01/26
Ruiz, Monica
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis	Recruiting	3	150	US, RoW	Saroglitazar Magnesium 1 mg	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/27	07/27
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC	Active, not recruiting	2	60	US	Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo	Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.	Primary Biliary Cholangitis	11/24	02/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
Dulce Digital, NCT05416060: 2.0 - Innovative Diabetes Self-Management in the Digital Age	Recruiting	N/A	150	US	Dulce Digital Text-Based Education, Project Dulce Telehealth, Project Dulce Live	Scripps Whittier Diabetes Institute	Diabetes Type 2	11/24	11/24